*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Recently published Phase IIa trial results in PLoS ONE show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals. Koronis is planning a follow-on Phase II trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
During this week’s podcast Dr. Mark Fromhold discusses the significance of the clinical trial findings and how a drug such as KP-1461 goes about doing its job. He also talks about Viral Decay Acceleration, which is the technique the company is using to develop antiviral therapies, and outlines the company’s strategy for turning KP-1461 into a clinical HIV therapeutic.
Mark G. Fromhold, Ph.D., is the vp of manufacturing and business development for Koronis Pharmaceuticals. He earned a BS in chemistry from Hope College followed by an MS in inorganic chemistry and a Ph.D. in organic chemistry from Indiana University.
Dr. Fromhold joined Koronis Pharmaceuticals from ICOS where he headed CMC development, strategic sourcing, and external GMP manufacturing for small molecule therapeutics. Prior to ICOS, Dr. Fromhold worked as a research scientist for Chiron and PathoGenesis, where he led CMC teams and headed process development and scale-up of numerous drug candidate molecules ranging from reverse transcriptase and kinase inhibitors to antibacterials.